Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Giulia Matusali, Alessandra Vergori, Eleonora Cimini, Davide Mariotti, Valentina Mazzotta, Alessandro Cozzi Lepri, Francesca Colavita, Roberta Gagliardini, Stefania Notari, Silvia Meschi, Marisa Fusto, Eleonora Tartaglia, Enrico Girardi, Fabrizio Maggi, Andrea Antinori
We estimated the dynamics of the neutralizing response against XBB sublineages and T cell response in persons with HIV (PWH) with previous AIDS and/or CD4 < 200/mm3 receiving the bivalent original strain/BA.4-5 booster dose in fall 2022. Samples were collected before the shot (Day 0), 15 days, 3, and 6 months after. PWH were stratified by immunization status: hybrid immunity (HI; vaccination plus COVID-19) versus nonhybrid immunity (nHI; vaccination only). Fifteen days after the booster, 16% and 30% of PWH were nonresponders in terms of anti-XBB...
April 2024: Journal of Medical Virology
#2
Lele Yu, Binhai Zhang, Hu Wan
INTRODUCTION: Kaposi sarcoma (KS) incidence has decreased since the initiation of combination antiretroviral therapy (cART), but it remains the most common cancer in people with HIV/AIDS (PWHA). PWHA with advanced immunosuppression who initiate antiretroviral therapy are susceptible to the occurrence of an immune reconstitution inflammatory syndrome (IRIS). CASE PRESENTATION: This report covers the case of a 25-year-old male with AIDS-related KS who relapsed after Liposomal Doxorubicin, but recovered well after administration of nab-paclitaxel (Nab-PTX)...
2024: Infection and Drug Resistance
#3
I M Magodoro, A C Castle, N Tshuma, J H Goedecke, R Sewpaul, J Manasa, J Manne-Goehler, Nab Ntusi, M J Nyirenda, M J Siedner
It is unclear how rising obesity among people with HIV (PWH) in sub-Saharan Africa (SSA) impacts their risk of type 2 diabetes mellitus (diabetes). Using a South African national cross-sectional sample of adult PWH and their peers without HIV (PWOH), we examined the associations between HIV and prevalent diabetes across the spectrum of body mass index (BMI), waist circumference (WC) and waist-to-height ratio (WtHR). Analyses were sex stratified, and adjusted for age, sociodemographic and behavioral factors...
March 14, 2024: medRxiv
#4
JOURNAL ARTICLE
Julia N Faraone, Xiaolwei Wang, Panke Qu, Yi-Min Zheng, Eunice Vincent, Huanbin Xu, Shan-Lu Liu
The evolution of SARS-CoV-2 paired with immune imprinting by prototype messenger RNA (mRNA) vaccine has challenged the current vaccination efficacy against newly emerged Omicron subvariants. In our study, we investigated a cohort of macaques infected by SIV and vaccinated with two doses of bivalent Pfizer mRNA vaccine containing wildtype and BA.5 spikes. Using a pseudotyped lentivirus neutralization assay, we determined neutralizing antibody (nAb) titers against new XBB variants, i.e., XBB.1.5, XBB.1.16, and XBB...
March 2024: Journal of Medical Virology
#5
REVIEW
Ee Hong Tam, Yu Peng, Megan Xin Yan Cheah, Chuan Yan, Tianshu Xiao
Neutralizing antibodies (NAbs) are naturally produced by our immune system to combat viral infections. Clinically, neutralizing antibodies with potent efficacy and high specificity have been extensively used to prevent and treat a wide variety of viral infections, including Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Human Immunodeficiency Virus (HIV), Dengue Virus (DENV) and Hepatitis B Virus (HBV). An overwhelmingly large subset of clinically effective NAbs operates by targeting viral envelope proteins to inhibit viral entry into the host cell...
February 17, 2024: Antiviral Research
#6
JOURNAL ARTICLE
Haoting Zhan, Yuchen Xie, Yongmei Liu, Linlin Cheng, Yi Xu, Xiaojing Qu, Chen Li, Xinru Guo, Haolong Li, Yuling Wang, Erhei Dai, Lijing Wang, Huixia Gao, Yongzhe Li
There is a paucity of data on hybrid immunity (vaccination plus breakthrough infection [BI]), especially cell-mediated responses to Omicron among immunosuppressed patients. We aim to investigate humoral and cellular responses to Omicron BA.4/5 among people living with HIV (PLWH) with/without BIs, the most prevalent variant of concern after the reopening of China. Based on our previous study, we enrolled 77 PLWH with baseline immune status of severe acute respiratory syndrome coronavirus 2 specific antibodies after inactivated vaccination...
February 2024: Journal of Medical Virology
#7
JOURNAL ARTICLE
Sorawit Chittrakarn, Pisud Siripaitoon, Sarunyou Chusri, Siripen Kanchanasuwan, Boonsri Charoenmak, Thanaporn Hortiwakul, Phaiwon Kantikit, Narongdet Kositpantawong
The immune response to heterologous coronavirus disease (COVID-19) vaccination in people living with HIV (PLWH) is still unclear. Herein, our prospective cohort study aimed to compare the immune response of heterologous vaccination with CoronaVac (Sinovac) and Vaxzevria (AstraZeneca) between PLWH having CD4 counts ≤ 200 cells/µL (low CD4+) and > 200 cells/µL (high CD4+). Anti-receptor-binding domain (RBD) immunoglobulin G (IgG) levels and the percentage inhibition of neutralizing antibodies (nAbs) were analyzed at 2 and 12 weeks after immunization...
December 31, 2024: Human Vaccines & Immunotherapeutics
#8
JOURNAL ARTICLE
Valentina Mazzotta, Alessandro Cozzi Lepri, Giulia Matusali, Eleonora Cimini, Pierluca Piselli, Camilla Aguglia, Simone Lanini, Francesca Colavita, Stefania Notari, Alessandra Oliva, Silvia Meschi, Rita Casetti, Vanessa Mondillo, Alessandra Vergori, Aurora Bettini, Germana Grassi, Carmela Pinnetti, Daniele Lapa, Eleonora Tartaglia, Paola Gallì, Annalisa Mondi, Giulia Montagnari, Roberta Gagliardini, Emanuele Nicastri, Miriam Lichtner, Loredana Sarmati, Enrica Tamburrini, Claudio Mastroianni, Christof Stingone, Andrea Siddu, Alessandra Barca, Carla Fontana, Chiara Agrati, Enrico Girardi, Francesco Vaia, Fabrizio Maggi, Andrea Antinori
BACKGROUND: Pre-exposure vaccination with MVA-BN has been widely used against mpox to contain the 2022 outbreak. Many countries have defined prioritized strategies, administering a single dose to those historically vaccinated for smallpox, to achieve quickly adequate coverage in front of low supplies. Using epidemiological models, real-life effectiveness was estimated at approximately 36%-86%, but no clinical trials were performed. Few data on MVA-BN immunogenicity are currently available, and there are no established correlates of protection...
February 2024: EClinicalMedicine
#9
JOURNAL ARTICLE
Yuxiao Wang, Xinquan Lan, Ying Qiao, Yuqi Huo, Li Wang, Shijie Liang, Maohe Yu, Moxin Song, Ying Yan, Bin Su, Junjie Xu
People living with HIV (PLWH) are particularly vulnerable to SARS-CoV-2. This multicentre prospective cohort study evaluated the long-term immunogenicity and safety of a third homologous dose of Sinovac CoronaVac in PLWH in China. A total of 228 PLWH and 127 HIV-negative controls were finally included and followed up for 6 months. Fewer participants reported mild or moderate adverse reactions, and no serious adverse events were observed. The median levels of neutralizing antibodies (nAbs) and immunoglobulin G against the receptor-binding domain of the spike protein (S-IgG) in PLWH (655...
January 2024: Journal of Medical Virology
#10
JOURNAL ARTICLE
Kevin O Saunders, James Counts, Bhishem Thakur, Victoria Stalls, Robert Edwards, Kartik Manne, Xiaozhi Lu, Katayoun Mansouri, Yue Chen, Rob Parks, Maggie Barr, Laura Sutherland, Joena Bal, Nicholas Havill, Haiyan Chen, Emily Machiele, Nolan Jamieson, Bhavna Hora, Megan Kopp, Katarzyna Janowska, Kara Anasti, Chuancang Jiang, Elizabeth Van Itallie, Sravani Venkatayogi, Amanda Eaton, Rory Henderson, Christopher Barbosa, S Munir Alam, Sampa Santra, Drew Weissman, M Anthony Moody, Derek W Cain, Ying K Tam, Mark Lewis, Wilton B Williams, Kevin Wiehe, David C Montefiori, Priyamvada Acharya, Barton F Haynes
The CD4-binding site (CD4bs) is a conserved epitope on HIV-1 envelope (Env) that can be targeted by protective broadly neutralizing antibodies (bnAbs). HIV-1 vaccines have not elicited CD4bs bnAbs for many reasons, including the occlusion of CD4bs by glycans, expansion of appropriate naive B cells with immunogens, and selection of functional antibody mutations. Here, we demonstrate that immunization of macaques with a CD4bs-targeting immunogen elicits neutralizing bnAb precursors with structural and genetic features of CD4-mimicking bnAbs...
January 4, 2024: Cell
#11
Brian D Williamson, Liana Wu, Yunda Huang, Aaron Hudson, Peter B Gilbert
Combination monoclonal broadly neutralizing antibodies (bnAbs) are currently being developed for preventing HIV-1 infection. Recent work has focused on predicting in vitro neutralization potency of both individual bnAbs and combination regimens against HIV-1 pseudoviruses using Env sequence features. To predict in vitro combination regimen neutralization potency against a given HIV-1 pseudovirus, previous approaches have applied mathematical models to combine individual-bnAb neutralization and have predicted this combined neutralization value; we call this the combine-then-predict (CP) approach...
December 14, 2023: bioRxiv
#12
JOURNAL ARTICLE
Alessandra Vergori, Alessandro Cozzi-Lepri, Giulia Matusali, Stefania Cicalini, Veronica Bordoni, Silvia Meschi, Valentina Mazzotta, Francesca Colavita, Marisa Fusto, Eleonora Cimini, Stefania Notari, Veronica D'Aquila, Simone Lanini, Daniele Lapa, Roberta Gagliardini, Davide Mariotti, Giuseppina Giannico, Enrico Girardi, Francesco Vaia, Chiara Agrati, Fabrizio Maggi, Andrea Antinori
(1) Background: Waning of neutralizing and cell-mediated immune response after the primary vaccine cycle (PVC) and the first booster dose (BD) is of concern, especially for PLWH with a CD4 count ≤200 cells/mm3 . (2) Methods: Neutralizing antibodies (nAbs) titers by microneutralization assay against WD614G/Omicron BA.1 and IFNγ production by ELISA assay were measured in samples of PLWH at four time points [2 and 4 months post-PVC (T1 and T2), 2 weeks and 5 months after the BD (T3 and T4)]. Participants were stratified by CD4 count after PVC (LCD4, ≤200/mm3 ; ICD4, 201-500/mm3 , and HCD4, >500/mm3 )...
November 22, 2023: Vaccines
#13
JOURNAL ARTICLE
Lindsay Wieczorek, Eric Sanders-Buell, Michelle Zemil, Eric Lewitus, Erin Kavusak, Jonah Heller, Sebastian Molnar, Mekhala Rao, Gabriel Smith, Meera Bose, Amy Nguyen, Adwitiya Dhungana, Katherine Okada, Kelly Parisi, Daniel Silas, Bonnie Slike, Anuradha Ganesan, Jason Okulicz, Tahaniyat Lalani, Brian K Agan, Trevor A Crowell, Janice Darden, Morgane Rolland, Sandhya Vasan, Julie Ake, Shelly J Krebs, Sheila Peel, Sodsai Tovanabutra, Victoria R Polonis
Subtype B HIV-1 has been the primary driver of the HIV-1 epidemic in the United States (U.S.) for over forty years and is also a prominent subtype in the Americas, Europe, Australia, the Middle East and North Africa. In this study, the neutralization profiles of contemporary subtype B Envs from the U.S. were assessed to characterize changes in neutralization sensitivities over time. We generated a panel of 30 contemporary pseudoviruses (PSVs) and demonstrated continued diversification of subtype B Env from the 1980s up to 2018...
December 2023: PLoS Pathogens
#14
JOURNAL ARTICLE
SARS-CoV-2 mRNA Vaccine Response in People Living with HIV According to CD4 Count and CD4/CD8 Ratio.
Alessandra Vergori, Alessandro Tavelli, Giulia Matusali, Anna Maria Azzini, Matteo Augello, Valentina Mazzotta, Giovanni Francesco Pellicanò, Andrea Costantini, Antonio Cascio, Andrea De Vito, Lorenzo Marconi, Elda Righi, Assunta Sartor, Carmela Pinnetti, Fabrizio Maggi, Francesca Bai, Simone Lanini, Stefania Piconi, Gabriel Levy Hara, Giulia Marchetti, Maddalena Giannella, Evelina Tacconelli, Antonella d'Arminio Monforte, Andrea Antinori, Alessandro Cozzi-Lepri, On Behalf Of The Vax-Icona-Orchestra Study
BACKGROUND: Our aim was to estimate the rates of not achieving a robust/above-average humoral response to the COVID-19 mRNA vaccine in people living with HIV (PLWH) who received ≥2 doses and to investigate the role of the CD4 and CD4/CD8 ratio in predicting the humoral response. METHODS: We evaluated the humoral anti-SARS-CoV-2 response 1-month after the second and third doses of COVID-19 mRNA vaccine as a proportion of not achieving a robust/above-average response using two criteria: (i) a humoral threshold identified as a correlate of protection against SARS-CoV-2 (<90% vaccine efficacy): anti-RBD < 775 BAU/mL or anti-S < 298 BAU/mL, (ii) threshold of binding antibodies equivalent to average neutralization activity from the levels of binding (nAb titer < 1:40): anti-RBD < 870 BAU/mL or anti-S < 1591 BAU/mL...
October 30, 2023: Vaccines
#15
JOURNAL ARTICLE
Philipp Schommers, Dae Sung Kim, Maike Schlotz, Christoph Kreer, Ralf Eggeling, Anna Hake, Melanie Stecher, Juyeon Park, Caelan E Radford, Adam S Dingens, Meryem S Ercanoglu, Henning Gruell, Stanley Odidika, Marten Dahlhaus, Lutz Gieselmann, Elvin Ahmadov, Rene Y Lawong, Eva Heger, Elena Knops, Christoph Wyen, Tim Kümmerle, Katja Römer, Stefan Scholten, Timo Wolf, Christoph Stephan, Isabelle Suárez, Nagarajan Raju, Anurag Adhikari, Stefan Esser, Hendrik Streeck, Ralf Duerr, Aubin J Nanfack, Susan Zolla-Pazner, Christof Geldmacher, Otto Geisenberger, Arne Kroidl, Wiston William, Lucas Maganga, Nyanda Elias Ntinginya, Ivelin S Georgiev, Jörg J Vehreschild, Michael Hoelscher, Gerd Fätkenheuer, Jason J Lavinder, Jesse D Bloom, Michael S Seaman, Clara Lehmann, Nico Pfeifer, George Georgiou, Florian Klein
Human immunodeficiency virus type 1 (HIV-1)-neutralizing antibodies (nAbs) that prevent infection are the main goal of HIV vaccine discovery. But as no nAb-eliciting vaccines are yet available, only data from HIV-1 neutralizers-persons with HIV-1 who naturally develop broad and potent nAbs-can inform about the dynamics and durability of nAb responses in humans, knowledge which is crucial for the design of future HIV-1 vaccine regimens. To address this, we assessed HIV-1-neutralizing immunoglobulin G (IgG) from 2,354 persons with HIV-1 on or off antiretroviral therapy (ART)...
November 2023: Nature Medicine
#16
JOURNAL ARTICLE
Karine Venegas Macieira, Diogo Gama Caetano, Sheila Maria Barbosa De Lima, Carmem Beatriz Wagner Giacoia-Gripp, Fernanda Heloise Côrtes, Andressa Da Silva Cazote, Adriana De Souza Azevedo Soares, Nathalia Dos Santos Alves, Marcel De Souza Borges Quintana, Marcellus Costa, Luciana Gomes Pedro Brandão, Michelle Morata De Andrade, Beatriz Grinsztejn, Lara Esteves Coelho, Dalziza Victalina De Almeida
Between 2016 and 2018, Brazil faced a yellow fever (YF) outbreak, which led to an expansion of vaccination coverage. The coexistence of the YF outbreak and the HIV-1 epidemic in Brazil raised concerns regarding the immune response and vaccine effectiveness in individuals living with HIV (PLWH). The aim of this study was to investigate the immune response to YF vaccination in PLWH and HIV-uninfected individuals as controls. Transcript levels of immunomodulatory molecules, including IL-6, IL-10, IL-21, TGF-β, CD19, CD163, miR-21, miR-146, and miR-155, were measured using RTqPCR...
November 10, 2023: Molecular Immunology
#17
JOURNAL ARTICLE
Rajesh P Ringe, Philippe Colin, Gabriel Ozorowski, Joel D Allen, Anila Yasmeen, Gemma E Seabright, Jeong Hyun Lee, Aleksandar Antanasijevic, Kimmo Rantalainen, Thomas Ketas, John P Moore, Andrew B Ward, Max Crispin, P J Klasse
Neutralizing antibodies (NAbs) to multiple epitopes on the HIV-1-envelope glycoprotein (Env) have been isolated from infected persons. The potency of NAbs is measured more often than the size of the persistent fraction of infectivity at maximum neutralization, which may also influence preventive efficacy of active or passive immunization and the therapeutic outcome of the latter. Many NAbs neutralize HIV-1 CZA97.012, a clone of a Clade-C isolate, to ~100%. But here NAb PGT151, directed to a fusion-peptide epitope, left a persistent fraction of 15%...
October 2023: PLoS Pathogens
#18
JOURNAL ARTICLE
Tyler D Evangelous, Madison Berry, Sravani Venkatayogi, Cas LeMaster, Eric S Geanes, Nicole De Naeyer, Todd DeMarco, Xiaoying Shen, Hui Li, Bhavna Hora, Nicholas Solomonis, Johnathan Misamore, Mark G Lewis, Thomas N Denny, David Montefiori, George M Shaw, Kevin Wiehe, Todd Bradley, Wilton B Williams
We recently found that a new pathogenic chimeric simian-human immunodeficiency virus (SHIV) elicited heterologous human immunodeficiency virus type-1 (HIV-1) neutralizing antibodies (nAbs) in therapy-naïve young rhesus macaques (RMs) following neonatal SHIV infection. Moreover, a subset of the SHIV-infected young RMs spontaneously controlled viremia. Here we evaluated humoral and cellular immunity and plasma biomarkers associated with spontaneous viremia suppression in a new model of young SHIV-infected RMs that generated heterologous HIV-1 nAbs independent of viremia control to gain insights into pediatric immunity that may be harnessed by appropriate therapies in HIV-1-infected infants and children...
October 24, 2023: Journal of Virology
#19
JOURNAL ARTICLE
Dalziza Victalina de Almeida, Priscila Alves Cezar, Thais Freitas Barreto Fernandes, Marcos Gustavo Araujo Schwarz, Leila Mendonça-Lima, Carmem Beatriz Wagner Giacoia-Gripp, Fernanda Heloise Côrtes, Monick Lindenmeyer Guimarães, Jose Henrique Pilotto, Nathalia Beatriz Ramos De Sá, Andressa da Silva Cazote, Larissa Rodrigues Gomes, Marcel de Souza Borges Quintana, Marcelo Ribeiro-Alves, Lara Esteves Coelho, Kim Mattos Geraldo, Maria Pia Diniz Ribeiro, Sandra Wagner Cardoso, Beatriz Grinsztejn, Valdiléa G Veloso, Mariza Gonçalves Morgado
The study provides valuable insights into the sociodemographic characteristics, clinical outcomes, and humoral immune response of those affected by the virus that has devastated every field of human life since 2019; the COVID-19 patients. Firstly, the association among clinical manifestations, comorbidities, and the production of neutralizing antibodies (Nabs) against SARS-CoV-2 is explored. Secondly, varying levels of Nabs among patients are revealed, and a significant correlation between the presence of Nabs and a shorter duration of hospitalization is identified, which highlights the potential role of Nabs in predicting clinical outcomes...
December 12, 2023: Microbiology Spectrum
#20
JOURNAL ARTICLE
Hong-Van Tieu, Shelly Karuna, Yunda Huang, Magdalena E Sobieszczyk, Hua Zheng, Georgia D Tomaras, David C Montefiori, Mingchao Shen, Stephen DeRosa, Kristen Cohen, Margaret Brewinski Isaacs, Stephanie Regenold, Jack Heptinstall, Kelly E Seaton, Sheetal Sawant, Brianna Furch, Michael Pensiero, Lawrence Corey, Katharine J Bar
BACKGROUND: An approach to a preventive HIV vaccine is induction of effective broadly neutralizing antibodies (bnAbs) and effector binding antibodies (bAbs). Preclinical studies suggest that trimeric envelope (Env) proteins may elicit nAbs, which led to the development of the recombinant gp145 subtype C Env protein (gp145 C.6980) immunogen. HVTN 122 was a Phase 1 trial that evaluated the safety, tolerability, and immunogenicity of gp145 C.6980 in adults. METHODS: Healthy, HIV-1 seronegative adults received three intramuscular injections of gp145 C...
September 5, 2023: Vaccine
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
